FY2026 operating margin DIPPED to 18.78% versus FY2025's 19.50% despite $362M in restructuring charges rolling off — stripping charges yields only ~19.7% versus FY25's 19.5%, a ~20bps improvement, not the 300-400bps expansion the bull projects.

• FY2026 operating margin: 18.78%
• FY2025 operating margin: 19.50%
• $362M restructuring charges
• ~19.7% stripped margin FY26
• 19.5% FY25 margin

↩ rebuts: “Bull's claim that restructuring charges rolling off translates directly to operating income expansion”

SG&A grew ~10% while revenue grew 8.4% — operating de-leverage, not leverage — potentially a sustained structural cost of defending market share against ISRG and Dexcom rather than temporary catch-up spend.

• SG&A grew ~10%
• Revenue grew 8.4%

↩ rebuts: “Bull's 'temporary commercial-spend catch-up' framing”

The stock trades at ~24× trailing earnings despite the bull arguing for 72% earnings acceleration — a skeptical market pricing the haircut into today rather than pricing the expansion.

• Stock trades ~24× trailing earnings
• Bull targets 14× forward
• 72% EPS expansion argument

↩ rebuts: “Bull's 14× forward valuation as entry point”

50 SMA at $85.14 is below the 200 SMA at $88.70 — a bearish moving average alignment that has not crossed to bullish; the 'golden cross' hasn't happened; the long-term trend structure remains negative.

• 50 SMA: $85.14
• 200 SMA: $88.70
• 50 < 200

↩ rebuts: “Bull's 'textbook mid-trend consolidation' technical framing”

200 SMA peaked at $90.95 in May 2026 and has declined every single month since — price at $89.97 is only $1.27 above a structurally falling resistance line, not a confident reclaim.

• 200 SMA peaked at $90.95 in May 2026
• Price: $89.97
• $1.27 above 200 SMA

↩ rebuts: “Bull's technical argument”

10 EMA peaked at $91.60 on 8/26; price gapped below it at $89.97 on 8/27; RSI dropped from 75 to 53 in 8 days — a 22-point decline not a 'soft reset'; ATR compression at pivot points often precedes volatility expansion to the downside.

• 10 EMA peaked at $91.60 on 8/26
• Price gapped below at $89.97 on 8/27
• RSI: 75 to 53 in 8 days
• ATR: $2.05 compressed

↩ rebuts: “Bull's 'healthy reset' framing of 10 EMA break”

MACD histogram at −0.27 with three consecutive declining bars — per Tom DeMark, three consecutive histogram bars is the threshold for a momentum shift signal; the bullish crossover from early July has produced its first momentum warning.

• MACD histogram: −0.27
• Three consecutive declining bars
• MACD line: +2.03

↩ rebuts: “Bull's 'pause' interpretation of MACD”

Zacks characterized the setup as having 'mixed beat signals' — analyst-speak for 'meet or modestly miss expectations'; lower bar does not mean upside asymmetry; Zacks framing explicitly cites tariffs and FX as 'clouding the outlook.'

• Zacks: 'mixed beat signals'
• Tariffs and FX cited as 'clouding the outlook'
• MDT has ~50% non-US revenue

↩ rebuts: “Bull's 'low bar = asymmetric setup' framing”

Hospital purchasing decisions operate on 3-5 year contract cycles and formulary committee approvals — they do NOT shift because a competitor had a single cybersecurity incident; the bull is importing a retail-trader framework into an institutional procurement reality.

• 3-5 year contract cycles
• BSX cyberattack and product recall on Aug 26

↩ rebuts: “Bull's BSX rotation tailwind thesis”

MDT is not immune to sector-wide cyber risk — BSX, a Fortune 500 medtech with dedicated cybersecurity infrastructure, was hit by an event that halted global order processing; the bull prices only BSX's problem as an MDT opportunity.

• BSX hit by cyber event halting global order processing

↩ rebuts: “Bull's asymmetric opportunity framing from BSX weakness”

ISRG has a 20-year robot installed base, surgeon training programs at hundreds of institutions, and ecosystem lock-in; MDT's Hugo is structurally disadvantaged in a category where ISRG has functional monopoly economics; Hugo 'in catch-up mode' is a polite way of saying 'we lost the robotics race.'

• ISRG: 100+ da Vinci 5 updates in progress
• 20-year robot installed base (ISRG)
• Hugo 'in catch-up mode'

↩ rebuts: “Bull's Hugo discount-as-opportunity thesis”

ISRG has positive tangible book, ~$35B cash, no long-term debt — the relevant comp for a medical devices franchise; MDT's −$3.27B tangible book, $26B long-term debt, and $42.6B goodwill (46% of total assets) is structurally inferior and represents constrained M&A capacity.

• ISRG: positive tangible book, ~$35B cash, no long-term debt
• MDT: −$3.27B tangible book
• $26B long-term debt
• $42.6B goodwill (46% of total assets)

↩ rebuts: “Bull's 'negative tangible book = industry norm' framing”

MDT spent $1B on buybacks last year, down from $3.2B in FY25 — the balance sheet cannot fund both debt reduction and bolt-on M&A ($2-10B per deal) simultaneously; goodwill impairment risk is real if Hugo, Simplera, or renal denervation underdeliver.

• Buybacks: $1B (last year), $3.2B in FY25

↩ rebuts: “Bull's M&A optionality narrative”

In 2022-23 Fed hiking cycle, MDT traded from $115 to $73 — a 36% drawdown; defensives get crushed once the multiple-expansion thesis breaks; 'higher for longer' is a floor on multiple compression, not a ceiling on expansion.

• MDT traded from $115 to $73 in 2022-23
• 36% drawdown
• Risk-free rate: 5%

↩ rebuts: “Bull's 'defensive in higher-for-longer' as a tailwind thesis”

8% recession probability has been trending UP (+1pp WoW); procedure volumes are elective and get deferred in recession; the bull's own framework cuts against MDT the moment recession probability crosses 15-20%.

• Recession probability: 8%
• +1pp WoW

↩ rebuts: “Bull's dismissal of recession risk”

The 90-day +19.95% return is mean reversion from the $73 trough — stocks that bottom after a -30% drawdown routinely post +20% 90-day moves; the 1-year total return of +2.09% tells you what long-term holders actually got.

• 90-day return: +19.95%
• 1-year total return: +2.09%
• $73 trough

↩ rebuts: “Bull's +19.95% 90-day return as evidence of new bull market”

MDT has had restructuring charges every fiscal year for the last decade — this is a structural feature of the operating model, not a one-time event; the bull is treating structural opex as transitory.

• Restructuring charges every fiscal year for the last decade

↩ rebuts: “Bull's 'restructuring savings drop to operating income' thesis”

If MDT guides FY27 EPS at $5.00–$5.50 instead of $6.40, the stock reprices to 17-18× forward immediately — a 15-20% drawdown; the downside from guide-down is much larger than upside from guide-up because the stock already prices optimistic operating leverage.

• Forward EPS consensus: $6.40
• Bear EPS scenario: $5.00–$5.50
• Repricing: 17-18× forward
• 15-20% drawdown scenario

↩ rebuts: “Bull's asymmetric setup claim”